Atacand (candesartan), a FDA-approved medication for high blood pressure (hypertension) was shown in a recent study to prevent cell injury associated with Alzheimer’s Disease.
This study showed candesartan worked in mouse cells and cell culture, both very early studies in the release of a new medication or new approved use for an existing one.
This study shows candesartin works in more than one way.
Well, one way is in treating high blood pressure or hypertension. Because high blood pressure is a risk factor for Alzheimer’s, this reduces that risk.
According to this study, candesartan also works by blocking damage to brain cells caused by glutamate. It appears to turn on genes that protect the cells from glutamate, and turns off others.
And, because candesartan is already FDA-approved, it’s approval for Alzheimer’s Disease could be reduced by years from a medication that has not yet been approved.
What is candesartan (Atacand)?
It’s part of the class or group of medications known as Angiotensin II Receptor Blockers (ARBs). They work by relaxing blood vessels, which in turn lowers blood pressure. The heart then works less hard pumping blood, which is why ARBs are used to treat hypertension and some forms of heart disease.
It’s exciting to think that studies of this drug could occur much sooner than a non-approved medication, although it still may be years before final approval is granted. And it’s also possible that other ARBs may have a similar effects. This is a hopeful report regarding treatment for Alzheimer’s Disease.